Trial Profile
Clinical Trials Insight: 700012677
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2021
Price :
$35
*
At a glance
- Drugs TGN 1412 (Primary)
- Indications Leukaemia; Multiple sclerosis; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors TeGenero
- 01 Apr 2021 Results published in the Cancer Immunology Immunotherapy
- 17 Mar 2006 New trial record.